ArticleThe American journal of pathology2002
Characterization of prostate cell types by CD cell surface molecules.
Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE).Nature biotechnology · 2008Guideline
- Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms.Cancers · 2025Review
- Editorial: Prostate cancer research: tools, cancer cell types, molecular targets.Frontiers in oncology · 2025Article
- Prostate cancer research: tools, cell types, and molecular targets.Frontiers in oncology · 2024Review
- Cancer-Associated Fibroblast Heterogeneity, Activation and Function: Implications for Prostate Cancer.Biomolecules · 2022Review
- Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment.Cancers · 2022Review
- Article
- Review
- A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra.Cell reports · 2018Article
- Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning.Nature biomedical engineering · 2018Article
- OMIP-040: Optimized gating of human prostate cellular subpopulations.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2017Article
- Cancer-secreted AGR2 induces programmed cell death in normal cells.Oncotarget · 2016Article
- Defined conditions for the isolation and expansion of basal prostate progenitor cells of mouse and human origin.Stem cell reports · 2015Article
- Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression.Oncotarget · 2015Review
- Reprogramming of prostate cancer cells--technical challenges.Current urology reports · 2015Review
- Cell surface antigen profiling using a novel type of antibody array immobilised to plasma ion-implanted polycarbonate.Cellular and molecular life sciences : CMLS · 2014Article
- Review
- Distinct function of estrogen receptor α in smooth muscle and fibroblast cells in prostate development.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes.Cell and tissue research · 2012Article
- Widespread expressions of immunoglobulin superfamily proteins in cancer cells.Cancer immunology, immunotherapy : CII · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A set of monoclonal antibodies raised against lymphocyte cell surface molecules, the cluster designation (CD) antigens, was used to distinguish the constituent cell types of the prostate. The luminal secretory epithelial, basal epithelial, fibromuscular stromal, nerve sheath, and endothelial cells express distinctive complements of cell surface molecules that were identified by immunohistochemistry using 152 commercially available antibodies. Many of the CD antibodies stained lymphocyte populations in the prostate. These lymphocyte populations were grouped into abundance classes of rare, moderate, and high. Some of these molecules are expressed by multiple cell types, both parenchymal and lymphoid; others are expressed by only one cell type. Distinctive patterns of CD expression, which are most similar to the expression pattern of prostate luminal cells, also characterize a small series of Gleason score 6 prostate cancers. The cell-type specificity of CD molecules increases the prospect of isolating specific cell populations, using such techniques as laser capture microdissection and flow cytometry, for cell-specific molecular studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.